JP7865948B2 - アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用 - Google Patents

アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用

Info

Publication number
JP7865948B2
JP7865948B2 JP2023514910A JP2023514910A JP7865948B2 JP 7865948 B2 JP7865948 B2 JP 7865948B2 JP 2023514910 A JP2023514910 A JP 2023514910A JP 2023514910 A JP2023514910 A JP 2023514910A JP 7865948 B2 JP7865948 B2 JP 7865948B2
Authority
JP
Japan
Prior art keywords
compound
disease
disorder
compounds
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023514910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540733A (ja
JP2023540733A5 (enExample
Inventor
マーク ジー． ボック
デイビッド ハリソン
ジェーン イー． スカンロン
Original Assignee
ノッドセラ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノッドセラ リミテッド filed Critical ノッドセラ リミテッド
Publication of JP2023540733A publication Critical patent/JP2023540733A/ja
Publication of JP2023540733A5 publication Critical patent/JP2023540733A5/ja
Application granted granted Critical
Publication of JP7865948B2 publication Critical patent/JP7865948B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023514910A 2020-09-04 2021-09-03 アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用 Active JP7865948B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063074521P 2020-09-04 2020-09-04
US63/074,521 2020-09-04
PCT/US2021/049001 WO2022051582A1 (en) 2020-09-04 2021-09-03 Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof

Publications (3)

Publication Number Publication Date
JP2023540733A JP2023540733A (ja) 2023-09-26
JP2023540733A5 JP2023540733A5 (enExample) 2024-09-09
JP7865948B2 true JP7865948B2 (ja) 2026-05-26

Family

ID=77951864

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514910A Active JP7865948B2 (ja) 2020-09-04 2021-09-03 アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用

Country Status (13)

Country Link
US (1) US20240043410A1 (enExample)
EP (1) EP4208459A1 (enExample)
JP (1) JP7865948B2 (enExample)
KR (1) KR20230061505A (enExample)
CN (1) CN116783184A (enExample)
AR (1) AR123435A1 (enExample)
AU (1) AU2021336518B2 (enExample)
BR (1) BR112023003792A2 (enExample)
CA (1) CA3191410A1 (enExample)
IL (1) IL301055A (enExample)
MX (1) MX2023002686A (enExample)
TW (1) TWI916398B (enExample)
WO (1) WO2022051582A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
HUE067378T2 (hu) 2019-06-12 2024-10-28 Nodthera Ltd Szulfonilurea származékok és alkalmazásaik
JP7661248B2 (ja) 2019-06-12 2025-04-14 ノッドセラ リミテッド スルホニル尿素誘導体及びその使用
KR20260115622A (ko) * 2023-11-17 2026-07-24 노드테라 리미티드 우레아 유도체의 제조 방법
CN122555701A (zh) 2023-11-17 2026-08-11 诺瑟拉有限公司 脲衍生物的形式和相关用途
TW202545527A (zh) * 2024-01-16 2025-12-01 英商諾得瑟拉公司 Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121691A1 (en) 2017-12-18 2019-06-27 NodThera Limited Sulphonyl urea derivatives as nlrp3 inflammasome modulators
WO2020035464A1 (en) 2018-08-15 2020-02-20 Inflazome Limited Novel sulfonamideurea compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
DK1270565T3 (da) 1997-01-29 2004-10-04 Pfizer 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121691A1 (en) 2017-12-18 2019-06-27 NodThera Limited Sulphonyl urea derivatives as nlrp3 inflammasome modulators
WO2020035464A1 (en) 2018-08-15 2020-02-20 Inflazome Limited Novel sulfonamideurea compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19"，Frontiers in Immunology，2020年05月19日，Vol. 11，Adnan SHAH，DOI: 10.3389/fimmu.2020.01021
Sandro Augusto RIBEIRO et al.，"The therapeutic potential of colchicine in the complications of COVID19. Could the immunometabolic properties of an old and cheap drug help?"，Metabolism Open，2020年09月，Vol. 7，p.100045，DOI: 10.1016/j.metop.2020.100045
Tracey L. FREEMAN et al.，"Targeting the NLRP3 Inflammasome in Severe COVID-19"，Frontiers in Immunology，2020年06月23日，Vol. 11，DOI: 10.3389/fimmu.2020.01518

Also Published As

Publication number Publication date
IL301055A (en) 2023-05-01
CA3191410A1 (en) 2022-03-10
TWI916398B (zh) 2026-03-01
BR112023003792A2 (pt) 2023-03-28
AU2021336518A1 (en) 2023-03-23
EP4208459A1 (en) 2023-07-12
AU2021336518B2 (en) 2026-05-21
MX2023002686A (es) 2023-04-03
AR123435A1 (es) 2022-11-30
JP2023540733A (ja) 2023-09-26
US20240043410A1 (en) 2024-02-08
KR20230061505A (ko) 2023-05-08
WO2022051582A1 (en) 2022-03-10
TW202229265A (zh) 2022-08-01
CN116783184A (zh) 2023-09-19

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260514

R150 Certificate of patent or registration of utility model

Ref document number: 7865948

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150